Pricing Log in Create free account
Saturday 17 October 2026 Export TGTX’s income statement to Excel — free account

TG Therapeutics, Inc.

TGTX Healthcare Biotechnology

TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024. In the quarter to June 2026, revenue grew 70.3%, EPS fell 73.7%, free cash flow grew 427.1% and total debt rose 204.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

53.97 2.03 −3.63%
Market cap
$8.6B
P/E
17.8×
Fwd P/E
29.4×
Dividend yield
—
F-score
5/9
Altman Z
6.29
Beneish M
0.80
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.44
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 — — — — — — — — — 1 —
Insider Ownership 0.09%

Capital & Financial Ratios $m

Market Cap 8,570.00
Revenue 799.54
Net Income 441.49
Free Cash Flow 17.39
Net Debt 193.14
Current Ratio 4.27 (at or above 1.5: strong)
Debt/Equity 1.23
P/E ratio 17.75
Fwd P/E 29.40
P/S ratio 9.57
P/B ratio 12.67 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth (63.91%) (below 0%: weak)
Next Y EPS Growth 187.56% (at or above 15%: strong)
Next Y revenue growth 55.82% (at or above 10%: strong)
Next 5Y EPS Growth 10.12%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 9.8×, against a ten-year median of 1,321×; over the ten years it ranged from 5.1× in 2023 to 35,702× in 2020.
P/S against its own 10 years 14.30%
10-year low 10-year high
P/B against its own 10 years 55.49%
10-year low 10-year high
EV/Sales against its own 10 years 15.63%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 218 311 142 552
Receivables 51 129 306 402
Inventory 40 110 126 148
Other 10 16 58 44
318 566 631 1,146
2023 2024 2025 Q'26
Payables 38 58 108 214
ST’ Debt — — — —
Other 1 5 2 1
54 91 154 268

Compound Annual Growth %

10y 5y 3y
Sales 129.45% 426.73% 504.86%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 20.36% 4.53% 122.81%

Revenue $m

Mar Jun Sep Dec Year
’26 205 240 — — —
’25 121 141 162 193 616
’24 63 73 84 108 329
’23 8 16 166 44 234
’22 2 1 0 0 3
’21 1 2 2 2 7
’20 0 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (18) 39 — — —
’25 (29) 7 (23) 20 (25)
’24 (8) 6 (12) (26) (41)
’23 (60) (42) 84 (13) (31)
’22 (69) (49) (34) (24) (176)
’21 (81) (60) (67) (87) (296)
’20 (62) (44) (57) (52) (215)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (18) 39 — — —
’25 (29) 7 (23) 20 (25)
’24 (8) 6 (12) (26) (41)
’23 (60) (42) 84 (13) (31)
’22 (69) (49) (34) (24) (176)
’21 (81) (60) (67) (87) (296)
’20 (62) (44) (57) (52) (215)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.12 0.05 — — —
’25 0.03 0.17 2.43 0.14 2.77
’24 (0.07) 0.04 0.02 0.15 0.15
’23 (0.28) (0.34) 0.73 (0.09) 0.09
’22 (0.51) (0.30) (0.26) (0.57) (1.46)
’21 (0.69) (0.59) (0.65) (0.70) (2.63)
’20 (0.48) (0.47) (0.73) (0.71) (2.42)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 4.50 4.10 3.32 3.87 6.34 12.62 3.48 6.46 12.84 25.28

Analyst estimates 2026–2028

Powerpack
High 11.76 15.35 17.35 11.42 56.11 56.74 20.69 35.67 36.84 46.48
People
People Employees 64 75 105 134 272 286 226 264 338 399
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.02 0.01 0.89 0.97 1.54
Income, $m
Income, $m Revenue 0 0 0 0 0 7 3 234 329 616
Gross margin, % 100.00 100.00 100.00 100.00 100.00 88.19 90.48 93.95 88.30 83.66
EBT (78) (118) (173) (173) (279) (348) (224) 13 26 107
EBT margin, % (51,482.24) (77,944.74) (114,132.89) (113,730.92) (183,803.29) (5,204.08) (8,036.34) 5.59 7.78 17.43
Net income (78) (118) (173) (173) (279) (348) (224) 13 23 447
Depreciation 1 0 0 1 1 2 2 1 (5) (2)
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.05 0.02 1.65 2.26 4.27
Earnings (1.60) (1.91) (2.15) (1.96) (2.42) (2.63) (1.46) 0.09 0.16 3.10
Cash flow (1.26) (1.51) (1.71) (1.50) (1.86) (2.24) (1.30) (0.22) (0.28) (0.17)
Capex (0.01) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Free cash flow (1.26) (1.51) (1.71) (1.50) (1.86) (2.24) (1.30) (0.22) (0.28) (0.17)
Book value 0.73 1.08 0.32 0.44 4.50 1.79 0.43 1.13 1.53 4.49
Shares, m 49 62 75 88 115 132 135 142 145 144
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 213.00 177.06 9.71
P/S 1,435.74 3,573.11 2,035.62 6,453.26 39,471.54 375.58 562.55 10.35 13.29 6.98
P/B 6.08 8.11 12.87 25.40 11.55 10.59 26.74 15.07 19.67 6.64
EV/Sales 1,141.20 3,016.52 1,583.09 5,731.82 35,702.31 338.65 530.39 9.85 13.10 7.15
EV/FCF (2.80) (4.89) (1.87) (6.55) (25.26) (7.65) (8.38) (73.26) (106.20) (176.37)
Cash, $m
Cash, $m Operating cash flow (62) (94) (129) (133) (215) (296) (176) (31) (41) (25)
Capex 0 0 0 0 0 0 0 — 0 0
Free cash flow (62) (94) (129) (133) (215) (296) (176) (31) (41) (25)
Balance, $m
Balance, $m Working capital 34 65 40 65 524 266 115 264 476 477
Total debt 0 0 0 31 33 68 71 100 244 246
Net debt (45) (85) (69) (110) (573) (247) (91) (117) (67) 104
Shareholders’ equity 36 67 24 39 519 237 59 161 222 648
Returns, %
Returns, % ROA (93.02) (155.72) (191.70) (140.19) (70.85) (69.26) (78.09) 4.84 5.15 54.50
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 29.91 16.82 10.25
ROE (113.87) (230.36) (381.16) (551.85) (100.14) (92.03) (151.36) 11.57 12.21 102.75
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

TG Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
KRYS Krystal Biotech, Inc. $9.8B 38.3× 38.6× +24.14% (above 0%: growing) +39.10% (above 0%: growing) +40.14% (above 0%: growing) 94.60% 49.00% Compare
KYMR Kymera Therapeutics, Inc. $9.0B — (loss-making) — (loss-making) +466.40% (above 0%: growing) n/m +9.97% (above 0%: growing) 100.00% (116.32%) Compare
CAI Caris Life Sciences,�Inc. $9.0B 81.3× 163× +45.38% (above 0%: growing) n/m +8.47% (above 0%: growing) 68.10% 10.21% Compare
CYTK Cytokinetics, Incorporated $8.9B — (loss-making) — (loss-making) −57.13% (below 0%: shrinking) n/m −24.02% (below 0%: shrinking) 80.46% (625.95%) Compare
PTGX Protagonist Therapeutics, Inc. $8.8B 106× 25.0× +3,749.17% (above 0%: growing) n/m +839.65% (above 0%: growing) 100.00% 74.37% Compare
TGTX TG Therapeutics, Inc. $8.6B 17.8× 29.4× +70.27% (above 0%: growing) −73.68% (below 0%: shrinking) +427.05% (above 0%: growing) 82.86% 9.02%
AXSM Axsome Therapeutics, Inc. $8.5B — (loss-making) — (loss-making) +45.54% (above 0%: growing) n/m −2.98% (below 0%: shrinking) 93.79% (22.73%) Compare
ARWR Arrowhead Pharmaceuticals, Inc. $8.3B — (loss-making) — (loss-making) +171.02% (above 0%: growing) n/m −15.43% (below 0%: shrinking) 100.00% (226.03%) Compare
ABVX Abivax SA Sponsored ADR $8.1B — (loss-making) — — n/m −48.28% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $8.9B 81.3× 38.6× +45.54% — +2.75% 94.20% (11.36%)

All 614 Biotechnology stocks →

TG Therapeutics, Inc. (TGTX) key facts

  • Strength: TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.
  • TG Therapeutics, Inc. (TGTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, TGTX traded at $53.97, a market capitalization of $8.6 billion.
  • Return on equity was 102.8% and debt-to-equity 1.23.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 6.29 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

TG Therapeutics, Inc. (TGTX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/TGTX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com